PRODUCT INFORMATION

Citrullinated α-Enolase (R8 + R14) (1-19)-biotin Peptide

Item No. 37627

Overview and Properties

Contents: This vial contains 1 mg of lyophilized peptide
Synonyms: Citrullinated Enolase-1-biotin, α-Enolase Peptide (Citrulline Residues 8 + 14)
Peptide Sequence: Biotin-SILKIHAXEIFDSXGNPTV (X=Citrulline)
Uniprot No.: P06733
Molecular Weight: 2,381.5
Form: Solid
Storage: -20°C (as supplied)
Stability: ≥3 years

Description

Citrullinated α-Enolase (R8 + R14) (1-19)-biotin peptide is a biotinylated and citrullinated form of a 19-amino acid N-terminal peptide fragment of α-enolase, a glycolytic enzyme that catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate.[1] α-Enolase also functions as a cell surface receptor for plasminogen on pathogens and activated immune cells, as an oxidative stress protein in endothelial cells, and as a chromatin binding partner to facilitate transcription.[2-4] α-Enolase is an autoantigen in asthma, Hashimoto's encephalopathy, and rheumatoid arthritis, and has been found in the serum of pediatric patients with juvenile idiopathic arthritis.[5-8] α-Enolase is also subject to citrullination by peptidyl arginine deiminases (PADs) and citrullinated α-enolase has been found in the synovial fluid of rheumatoid arthritis patients.[7] Cayman's Citrullinated α-Enolase (R8 + R14) (1-19)-biotin Peptide is intended for use in the detection of autoantibodies against α-enolase citrullinated at R8 and R13.

References

1. Zhu, X., Miao, X., Wu, Y., *et al.* ENO1 promotes tumor proliferation and cell adhesion mediated drug resistance (CAM-DR) in non-Hodgkin's lymphomas. *Exp. Cell Res.* **335(2),** 216-223 (2015).
2. Song, Y., Luo, Q., Long, H., *et al.* Alpha-enolase as a potential cancer prognostic marker promotes cell growth, migration, and invasion in glioma. *Mol. Cancer* **13,** 65 (2014).
3. Subramanian, A. and Miller, D.M. Structural analysis of α-enolase. Mapping the functional domains involved in down-regulation of the *c-myc* protooncogene. *J. Biol. Chem.* **275(8),** 5958-5965 (2000).
4. Hsiao, K.-C., Shih, N.-Y., Fang, H.-L., *et al.* Surface α-enolase promotes extracellular matrix degradation and tumor metastasis and represents a new therapeutic target. *PLoS One* **8(7),** e69354 (2013).
5. Nahm, D.-H., Lee, K.-H., Shin, J.-Y., *et al.* Identification of α-enolase as an autoantigen associated with severe asthma. *J. Allergy Clin. Immunol.* **118(2),** 376-381 (2006).
6. Moore, T.L., Gillian, B.E., Crespo-Pagnussat, S., *et al.* Measurement and evaluation of isotypes of anti-citrullinated fibrinogen and anti-citrullinated α-enolase antibodies in juvenile idiopathic arthritis. *Clin. Exp. Rheumatol.* **32(5),** 740-746 (2014).
7. Yoneda, M., Fujii, A., Ito, A., *et al.* High prevalence of serum autoantibodies against the amino terminal of α-enolase in Hashimoto's encephalopathy. *J. Neuroimmunol.* **185(1-2),** 195-200 (2007).
8. Cong, Y., Wang, L., Peng, R., *et al.* Timosaponin AIII induces antiplatelet and antithrombotic activity *via* Gq-mediated signaling by the thromboxane A2 receptor. *Sci. Rep.* **6,** 38757 (2016).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM